BOONTON, N.J., March 15, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), today announced the appointment of David Moskowitz, RPh, MBA, to the position of Chief Financial Officer. In this newly created position, Mr. Moskowitz will serve as a member of the company's executive leadership team and lead the strategic direction of Unigene's financial and capital markets activities. Mr. Moskowitz joins Unigene after spending the previous 13 years as a top-rated equity research analyst covering large-cap pharmaceutical, specialty pharmaceutical, biotechnology, and generic drug companies. Most recently, Mr. Moskowitz served as a senior pharmaceutical analyst for Roth Capital Partners, LLC where he developed research coverage of emerging specialty pharma and biotechnology companies. Mr. Moskowitz received the 2011 StarMine Analyst Award as the top stock picker among U.S. Biotechnology Analysts. Ashleigh Palmer, President and CEO of Unigene, stated, "We are extremely excited to welcome David to Unigene and look forward to benefiting from his in-depth knowledge of the pharmaceutical market space, strategic financial perspective, industry and Wall Street network, and strong credibility and reputation within the investment community. In executing Unigene's turnaround strategy, we recognized the appointment of a chief financial officer would be a critical step in accelerating the next phase of our growth and addressing the priority challenge for Unigene in 2012, our substantial debt. Given the profound significance of this new role for Unigene, the person assuming the position must possess superior strategic, analytical and financial capabilities, while having a keen understanding of the numerous dynamics at play within the pharmaceutical industry. I have no doubt whatsoever that David is the individual we have been searching for." Prior to his position at Roth Capital, Mr. Moskowitz held directorial and senior-level pharmaceutical and healthcare equity analyst positions with Madison Williams & Co., Caris & Co., Friedman Billings Ramsey & Co., UBS Warburg, LLC, and Standard & Poor's. Mr. Moskowitz remarked, "I have spent the better part of my career analyzing the pharmaceutical industry with a contrarian focus and, in particular, identifying those companies poised to redefine a therapeutic category and market. Having closely followed the Company for almost a year, without question, Unigene represents such an opportunity. Its validated Peptelligence™ oral peptide delivery platform and exciting, late-stage development pipeline have enabled Unigene to carve out a position as the leader in what I believe will be one of the next great patient-treatment and therapeutic breakthroughs – the transition of peptides from injectable to oral delivery."